Compare Moderna, Inc. (MRNA) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Taskus Inc — how do they compare? Moderna, Inc. trades at $135.97 (market cap $56.02B), while Taskus Inc trades at $7.59 (market cap $700.49M). The key difference: Moderna, Inc. is far larger — about 80× Taskus Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | TASK | |
|---|---|---|
Market Cap | $56.02B | $700.49M |
Sector | Health | Technology |
52-Week High | $174.38 | $18.03 |
52-Week Low | $22.36 | $4.57 |
Enterprise Value | $52.17B | $1.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
TaskUs (TASK) trades at $7.65, down 3.29% today, with technical indicators showing neutral momentum. The company demonstrates strong fundamentals with revenue growth to $1.18B in 2025 and net income of $102.28M, yielding attractive valuation ratios including a P/E of 6.59 and P/S of 0.58. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.28 expected, driven by AI Services growth.
The stock presents value opportunity with discounted multiples and analyst consensus target of $8.00 (4.6% upside). Risks include client concentration and competitive pressures in digital services. Institutional interest remains positive with Dimensional Fund increasing holdings by 12.8% in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
